SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : AMLN (DIABETES DRUGS)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: David Bogdanoff who wrote (967)11/20/1997 8:57:00 PM
From: D.Right  Read Replies (1) of 2173
 
Dear David:

I have a question for you. AMLN increased its patients number in the type I trials from 400 to 480. If they have four groups there for each trial, that will increase the number from 100 to 120 per group. Is that really significant? They mentioned in their news release that it was because they wanted to increase the chance to be statisticly significant for subgroups. I think what they are doing is to try to get neough patients who use steady level insulin as a sup-group because even if they try to control the amount of insulin used by patients, some will use more or less as they wish.

Thanks

D.Right
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News